Hypermarcas (OTCMKTS:HYPMY) Stock Price Down 4.9% – Here’s Why

Hypermarcas (OTCMKTS:HYPMY) shares dropped 4.9% on Friday . The stock traded as low as $4.61 and last traded at $4.61. Approximately 8,543 shares changed hands during mid-day trading, a decline of 84% from the average daily volume of 54,724 shares. The stock had previously closed at $4.85.

Hypermarcas Stock Down 4.9%

The company has a debt-to-equity ratio of 0.63, a current ratio of 1.26 and a quick ratio of 0.80. The company has a 50-day moving average of $4.36 and a two-hundred day moving average of $4.46. The company has a market capitalization of $2.92 billion, a PE ratio of 20.04 and a beta of 0.82.

Hypermarcas (OTCMKTS:HYPMY) last released its earnings results on Wednesday, November 12th. The company reported $0.13 earnings per share for the quarter. The company had revenue of $408.83 million for the quarter. Hypermarcas had a net margin of 12.03% and a return on equity of 6.99%.

About Hypermarcas

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.